Search Results

Sparrow Pharmaceuticals, announced today that it will be attending the Endocrine Society (ENDO) 2024 Annual Conference.

Sparrow Pharmaceuticals presented data from an ongoing Phase 2 clinical trial of HSD-1 inhibitor clofutriben and prednisolone in patients with polymyalgia rheumatica at the 2024 Annual European Alliance for Associations for Rheumatology that suggest HSD-1 inhibition can allow for effective treatment with glucocorticoid medicines with fewer side effects.

Sparrow Pharmaceuticals will present interim results from a Phase 2 clinical trial of its novel HSD-1 inhibitor, clofutriben (SPI-62), administered in combination with prednisolone to patients with polymyalgia rheumatica, at the European Congress of Rheumatology (EULAR) 2024 congress in Vienna, Austria during a highlighted session, “The 75th Anniversary of Glucocorticoids - what have we learnt?”

Sparrow BioAcoustics [Sparrow], a pioneer in the field of bioacoustics technology, announces the launch of Stethophone™, a groundbreaking advancement in personalized heart health, exclusively on Valentine’s Day, February 14, 2024.

Sparrow Pharmaceuticals today announced that the first patient has been dosed in the Phase 2 ACSpire study (NCT number: NCT05436639 ) of SPI-62.

Sparrow Pharmaceuticals has expanded its PROST! Phase 2 clinical trial (NCT number: NCT05436652 ) of SPI-62 in combination with prednisolone for the treatment of polymyalgia rheumatica (PMR) to include a third cohort.

Sparrow BioAcoustics today announced it has received clearance from the U.S. Food and Drug Administration to market its software that allows smartphones to be used as medical stethoscopes.